Abstract Library

#3969 A case report of a high-grade pancreatic NET patient with high tumor mutation burden who benefited from chemotherapy combined with immunotherapy

Introduction: For patients with well-differentiated G3 NET, the efficacy of immune checkpoint inhibitors (ICIs) is currently not clear. The expression level of PD-L1 in tumor tissue, high microsatellite instability (MSI-H), and high tumor mutational burden (TMB-H) are considered indicators for selecting potential beneficiaries of immunotherapy.

Conference:

Presenting Author:

Authors: Jia X, Liang Y, Chen J,

Keywords: g3 pancreatic net, captem, tmb-h, icis,

#3633 Tumor mutation burden in gastroenteropancreatic neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are rare tumors with limited treatment options. Microsatellite instability (MSI) and tumor mutation burden (TMB) are novel biomarkers in various tumor types. However, few studies have been performed for these novel biomarkers in gastroenteropancreatic (GEP)- NENs.

Conference:

Presenting Author: Sun Young J

Authors: Sun Young J, Seung Tae K, Young Suk P, Jeeyun L,

Keywords: tumor mutation burden, neuroendocrine tumor, neuroendocrine carcinoma, gastroenteropancreatic neuroendocrine neoplasm,

#3287 Utilization of next generation sequencing in NET/NEC management and practice patterns: A prospective survey of global NET specialists

Introduction: Next generation sequencing based somatic tumor mutation as well as germline mutation data is being increasingly used in cancer management. Pan tumor type FDA approval for NTRK fusion, intermediated-high tumor mutation burden and MSI high status has paved way for tissue agnostic molecularly targeted therapies. Utilization of NGS in neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC) is currently unknown.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Chauhan A, Munir A, Hernando J, Leeuwaarde R, Zhang P,

Keywords: NGS, NEC, NET,

#2143 Efficacy and Safety of Anti-PD-1 Antibody (IBI308) in Treating Advanced Neuroendocrine Neoplams

Introduction: Neuroendocrine neoplasms (NENs) are a series of disease which show highly heterogeneity but have limited treatment options. Previous studies showed that tumor mutation burden (TMB) in NEC was relatively high which is considered as a predictive marker of anti-PD-1 antibody.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Xu J

Authors: Jia R, Li Y, Jin Y, Chen Y, Zhang Y,

Keywords: NEC, checkpoint blockade, anti-PD-1 antibody, NENs,